valproic acid has been researched along with Lymphoma in 6 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling." | 7.81 | Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. ( Cheng, S; Janin, A; Ji, MM; Liu, H; Shen, Y; Wang, L; Xu, PP; Xue, W; Zhan, Q; Zhao, WL; Zhao, X; Zhao, Y, 2015) |
| "Enzastaurin is an investigational PKCĪ² inhibitor that has growth inhibitory and pro-apoptotic effects in both B and T-cell lymphomas." | 7.77 | HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. ( Almasan, A; Bodo, J; Hsi, ED; Maciejewski, JP; Sedlak, J, 2011) |
| " The HDAC (histone deacetylase) inhibitor valproic acid (VPA) interacted synergistically with chemotherapeutic agents to trigger lymphoma cell autophagy, which resulted from activation of AMPK (AMP-activated protein kinase) and inhibition of downstream MTOR (mechanistic target of rapamycin [serine/threonine kinase]) signaling." | 3.81 | Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation. ( Cheng, S; Janin, A; Ji, MM; Liu, H; Shen, Y; Wang, L; Xu, PP; Xue, W; Zhan, Q; Zhao, WL; Zhao, X; Zhao, Y, 2015) |
| "Enzastaurin is an investigational PKCĪ² inhibitor that has growth inhibitory and pro-apoptotic effects in both B and T-cell lymphomas." | 3.77 | HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells. ( Almasan, A; Bodo, J; Hsi, ED; Maciejewski, JP; Sedlak, J, 2011) |
| " In conclusion, we identified HSPA1A as a possible therapeutic target, in combination with HDACi, for lymphoid neoplasms." | 1.38 | Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms. ( Fujii, K; Hamada, T; Ikeda, K; Iwatsuki, K; Kondo, T; Suzuki, N; Yamamoto, T, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, MM | 1 |
| Wang, L | 1 |
| Zhan, Q | 1 |
| Xue, W | 1 |
| Zhao, Y | 1 |
| Zhao, X | 1 |
| Xu, PP | 1 |
| Shen, Y | 1 |
| Liu, H | 1 |
| Janin, A | 1 |
| Cheng, S | 1 |
| Zhao, WL | 1 |
| Bodo, J | 1 |
| Sedlak, J | 1 |
| Maciejewski, JP | 1 |
| Almasan, A | 1 |
| Hsi, ED | 1 |
| Fujii, K | 1 |
| Suzuki, N | 1 |
| Ikeda, K | 1 |
| Hamada, T | 1 |
| Yamamoto, T | 1 |
| Kondo, T | 1 |
| Iwatsuki, K | 1 |
| Sakajiri, S | 1 |
| Kumagai, T | 1 |
| Kawamata, N | 1 |
| Saitoh, T | 1 |
| Said, JW | 1 |
| Koeffler, HP | 1 |
| Klass, CM | 1 |
| Krug, LT | 1 |
| Pozharskaya, VP | 1 |
| Offermann, MK | 1 |
| Tittle, TV | 1 |
| Schaumann, BA | 1 |
| Rainey, JE | 1 |
| Taylor, K | 1 |
6 other studies available for valproic acid and Lymphoma
| Article | Year |
|---|---|
Induction of autophagy by valproic acid enhanced lymphoma cell chemosensitivity through HDAC-independent and IP3-mediated PRKAA activation.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Synergism; E | 2015 |
HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; | 2011 |
Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Screening Assays, Antitu | 2012 |
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation | 2005 |
The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production.
Topics: Antiviral Agents; Apoptosis; Cell Line; DNA-Directed DNA Polymerase; Foscarnet; Ganciclovir; Herpesv | 2005 |
Segregation of the growth slowing effects of valproic acid from phenytoin and carbamazepine on lymphoid tumor cells.
Topics: Carbamazepine; Cell Division; Culture Techniques; Humans; Kinetics; Leukemia; Lymphoma; Phenytoin; R | 1992 |